Related Experiment Video
Updated: Feb 7, 2026

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and
Xin-Shuai Wang1, Xue-Zhen Ding1, Xiao-Cen Li2
1Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Abstract:
The prognosis of esophageal squamous cell carcinoma is poor. We hereby presented a highly integrated and clinically relevant precision nanomedicine strategy to target ESCC molecularly and physically for significant improvement of the treatment efficacy. We firstly identified PI3K overexpression in patient samples and its relation to poor patient survival. With our highly versatile tumor-targeted drug delivery platform (DCM), we were able to load a potent but toxic docetaxel (DTX) and a PI3K inhibitor (AZD8186) with favorable physical properties. The combination of the DTX-DCM and AZD8186-DCM showed a highly efficacious and synergistic anti-tumor effect and decreased hematotoxicity. A pro-apoptotic protein, Bax was significantly upregulated in ESCC cells treated with combination therapy compared to that with monotherapy. This study utilized a highly integrated precision nano-medicine strategy that combines the identification of cancer molecular target from human patients, precision drug delivery and effective combination therapy for the development of better ESCC treatment.
Insights
This study introduces a novel nanomedicine approach for esophageal squamous cell carcinoma (ESCC) treatment. Combining targeted drug delivery of docetaxel and a PI3K inhibitor significantly improved efficacy and reduced side effects in ESCC.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Esophageal squamous cell carcinoma (ESCC) has a poor prognosis, necessitating improved therapeutic strategies.
- PI3K pathway is frequently overexpressed in ESCC and correlates with reduced patient survival.
- Current ESCC treatments often face challenges with efficacy and significant toxicity.
Purpose of the Study:
- To develop and evaluate a precision nanomedicine strategy for targeting ESCC.
- To investigate the synergistic anti-tumor effects of combining docetaxel (DTX) and a PI3K inhibitor (AZD8186) delivered via a nanomedicine platform.
- To assess the impact of this combination therapy on tumor response and systemic toxicity.
Main Methods:
- Identification of PI3K overexpression in ESCC patient samples.
- Development of a versatile tumor-targeted drug delivery platform (DCM) capable of co-delivering DTX and AZD8186.
- In vitro evaluation of the combined nanomedicine therapy's efficacy, synergy, and impact on apoptosis-related proteins (Bax).
- Assessment of hematotoxicity associated with the combination therapy compared to monotherapy.
Main Results:
- The nanomedicine platform (DCM) successfully co-delivered DTX and AZD8186.
- Combination therapy demonstrated highly efficacious and synergistic anti-tumor activity against ESCC.
- Treatment with the combined DTX-DCM and AZD8186-DCM significantly upregulated the pro-apoptotic protein Bax.
- The combination therapy resulted in decreased hematotoxicity compared to monotherapy.
Conclusions:
- A highly integrated precision nanomedicine strategy targeting molecular (PI3K) and physical aspects of ESCC was developed.
- This approach offers a promising avenue for significantly improving ESCC treatment efficacy through synergistic combination therapy.
- The study highlights the potential of precision nanomedicine in advancing cancer treatment by integrating patient-specific targets with advanced drug delivery systems.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Uncertainty in Measurement: Accuracy and Precision
Molecular Models
Esophageal Varices-I: Introduction
Physical and Chemical Properties of Matter
Esophageal Perforation-I: Introduction
The location of esophageal perforation can vary, occurring anywhere along the esophagus....

